CompletedPhase 1NCT02493738

A Clinical Study to Evaluate the Pharmacokinetics of Lozanoc and Sporanox in Korean Healthy Male Volunteers

Studying Histoplasmosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Boryung Pharmaceutical Co., Ltd
Principal Investigator: Kyun-Seop Bae, M.D., Ph.D.
Department of Clinical Pharmacology and Therapeutics, Asan Medical Center
Intervention: Lozanoc 50mg(drug)
Enrollment: 24 target
Eligibility: 19-50 years · MALE
Timeline: 2015 – 2015

Study locations (1)

Asan Medical Center, Seoul, South Korea

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02493738 on ClinicalTrials.gov

Other trials for Histoplasmosis

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE3NCT05814432
Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS
Federal University of Health Science of Porto Alegre

See all trials for Histoplasmosis →

← Back to all trials